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Abstract
Acute and chronic pain control is a significant clinical challenge that has been largely unmet. 
Local anesthetics are widely used for the control of post-operative pain and in the therapy of acute 
and chronic pain. While a variety of approaches are currently used to prolong the duration of 
action of local anesthetics, an optimal strategy to achieve neural blockage for several hours to days 
with minimal toxicity has yet to be identified. Several drug delivery systems such as liposomes, 
microparticles and nanoparticles have been investigated as local anesthetic delivery vehicles to 
achieve prolonged anesthesia. Recently, injectable responsive hydrogels raise significant interest 
for the localized delivery of anesthetic molecules. This paper discusses the potential of injectable 
hydrogels to prolong the action of local anesthetics.
Pain is the most common presenting complaint to physicians as a result of accidental or 
sports related injuries and various diseases. A number of factors influence an individual’s 
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reaction to pain including age, cultural background, perception, past experiences, social 
expectations, physical and mental health, parental attitudes concerning pain, fear, anxiety, 
fatigue and the setting in which pain occurs [1,2]. The experience of pain can be broadly 
classified into acute and chronic pain [3]. Acute pain can be modulated and removed by 
treating its cause and is usually a sequel to surgery or trauma. Chronic pain is more complex 
and the source of pain may be difficult to eliminate. Relieving pain has been shown to result 
in improved healing, faster recovery and an earlier return to former activities and lifestyle 
[4].
The two major classes of analgesics used for treating pain are opioids and nonsteroidal anti-
inflammatory drugs (NSAIDs). The primary mode of action of these analgesics differs; 
some act centrally, some peripherally and others exert their effect at multiple locations. 
First-line treatments for pain usually involve nonopioid analgesic agents including aspirin, 
paracetamol and NSAIDs. These nonopioid analgesics have advantageous in relieving acute 
pain because they are readily available without a prescription, relatively inexpensive and 
easy to use. However, many of these nonopioid drugs may only be effective for mild to 
moderate pain. For patients with moderate to severe pain, opioid analgesics or nonopioid 
analgesics combined with other analgesic agents are considered. Opioids such as morphine 
are considered as the gold standard for the management of pain [5]. However, opioid 
treatments are often associated with a wide range of side effects such as splinting, sedation, 
nausea, vomiting, impaired bowel motility and development of tolerance (particularly in the 
case of chronic pain management) [6]. Even though opioids are known to produce analgesia 
primarily through their actions in the central nervous system, studies have shown the 
presence and activation of peripheral opioid receptors in painful inflammatory conditions 
[7]. These drugs provide a critical armamentarium of pain management options and 
continued research toward development of more potent, more site specific, less toxic and 
less abusable molecules will further enhance their utility.
The use of local anesthetics to treat pain has many potential advantages compared with the 
systemic administration of opioid analgesics, in situations where the cause and source of the 
pain is limited to a particular site or region [8]. It is often used as an adjunct to systemic 
analgesia, or to provide epidural or anesthesia. Offsetting the use of opioids and NSAIDS 
with local blockade permits the use of smaller amounts of systemic drugs, thus lowering 
risks of side effects and potential toxicity. Natural-derived and synthetic local anesthetic 
molecules, specifically amino amides and amino esters, are currently under investigation 
(Table 1) [9]. Common local anesthetics include bupivicaine, chloroprocaine, lidocaine, 
procaine and tetracaine. They work by numbing the target area without causing 
unconsciousness. The underlying molecular mechanism of local anesthetics is mainly the 
inhibition of sodium influx through voltage-gated sodium-specific ion channels in the 
neuronal cell membrane, which prevents transmission of nerve impulses where local 
anesthetics are applied [10]. Recent research efforts have been focused on establishing 
appropriate formulations in order to optimize therapeutic efficacy [11]. For instance, eutectic 
mixture of local anesthetics, known as EMLA, is a mixture of equal amounts of two well-
known local anesthetics, prilocaine and lidocaine. EMLA is designed for topical anesthesia 
during blood sampling, placement of intravenous cannulae and minor superficial procedures 
[12,13]. Similarly, a eutectic mixture of lidocaine and tetracaine is used to numb the skin 
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before certain minor procedures [12] and tetracaine-epinephrine-cocaine (TAC) solution is 
indicated as a local dermal anesthetic for the emergency treatment of uncomplicated 
lacerations [14]. While promising, utilizing synthetic local anesthetic formulations has the 
potential to cause significant health issues, such as systemic toxicity and adverse local tissue 
reaction [9,11,15,16].
Current research, therefore, has been focused on the identification of novel local anesthetics 
with protracted analgesic effect and minimal toxicity. Pharmacological studies have revealed 
the potent analgesic activity of several neurotoxins isolated from animals, plants and marine 
organisms. These naturally derived molecules are of particular interest because of their 
strong pharmacological activity, selectivity, low cytotoxicity and specificity for the site of 
action. For instance, α-cobratoxin (α-CTx), isolated from the Thailand Cobra, has strong 
affinity for the α7 subunit of the nAChR (α7nAChR) neuronal receptor [17], which is 
predominantly located in the peripheral nervous system. It is believed that activation of 
α7nAChR by αCTx leads to the depolarization of postsynaptic membranes and the 
prevention of neurotransmitter release [18]. Thus, αCTx has significant potential to serve as 
a new regimen to combat localized pain with long-lasting analgesic activity, nondependence, 
relatively low cost and commercial availability [19]. More well-controlled clinical studies 
are needed to establish the benefits of utilizing naturally derived local anesthetics on 
patients. In addition, future research will be able to identify additional analgesic molecules 
for localized pain relief that are more affordable, safer and have longer lasting effects 
compared with the presently available medications.
Several biomaterial based controlled delivery systems are currently been investigated as an 
alternative approach to extend the activity of fast-acting local anesthetic molecules. 
Controlled delivery local anesthetic formulations have the potential to serve as a safe, 
localized, long-acting postoperative pain management system. Several carriers including 
liposomes, microparticles and nanoparticles have been investigated with some success; 
however, they can freely diffuse from the injection site presenting limitations for long-term 
localized anesthesia. Recently, research has been focused on developing responsive 
hydrogel carriers as unique delivery vehicles for local anesthetic molecules. The review 
focuses on the recent advances in the area of hydrogel based carriers for prolonged delivery 
of local anesthetic molecules.
Long-acting local anesthetics for orthopedic applications
The usage of long-acting local anesthetics in the management of chronic pain in 
orthopaedics is twofold: to enable diagnosis of some chronic pain conditions and to provide 
relief for some nonsurgical pain conditions [20,21]. Table 2 shows some chronic pain 
diagnoses in which local anesthetics play a role in treatment and management:
Clinically, local anesthetics cause a reversible loss of nociception and local anesthesia. In 
the treatment of chronic pain, local anesthetics can be applied to a number of tissues, 
including nerve, joint and muscle. When used on nerve structures (nerve block), specific 
local anesthetic effects include analgesia (loss of pain sensation) and paralysis (loss of 
muscle power). A delicate balance between these two effects, analgesia and paralysis, must 
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be obtained to optimally treat patients clinically. For the treatment of chronic pain, which is 
typically an outpatient service, analgesia rather than paralysis is the desired effect by a 
number order of magnitude. Simply put, the clinician wants the patient to have reduced pain 
but to be able to walk out of the office and go back home. Thus, a local anesthetic with a 
longer duration of action and a potency that gives a sensory block with minor motor block 
would be very valuable for the practicing clinician.
Spinal facet joint mediated pain is diagnosed with either an intra-articular joint injection or a 
medial branch nerve block. A longer acting injectable local anesthetic, one that lasts 7–20 
days, can give the patient longer pain relief so as to complete a course of physical therapy or 
lend to specific diagnosis. This may also be true with the diagnosis of SI joint mediated 
pain, which is diagnosed similarly to facet joint mediated pain. In myofacial pain 
syndromes, such as trigger points and fibromyalgia, physical therapy is the mainstay of 
treatment. Local anesthetic injections are used to cause analgesia in the painful muscles 
while a patient completes physical therapy. The longer acting the medication is (e.g., 7–20 
days), the fewer injections the patient will need during an 8 to 12 week course of physical 
therapy. A longer acting local anesthetic can also assist with long-term treatment and 
diagnosis of sympathetically mediated pain syndromes such as complex regional pain 
syndromes of the extremities. Lastly, localized peripheral neuropathies, such as meralgia 
paresthetica and occipital neuralgia, are typically treated with long-acting local anesthetics.
Clinically the duration of action, toxicities and patient-specific factors (such as allergies) 
largely determine the choice of anesthetics used. The currently used depo-long acting 
versions of the injectable local anesthetics provide prolonged anesthesia due to the inherent 
structure of the anesthetic rather than from the delivery mechanism. Examples include 
lidocaine (moderate potency and duration), procaine (low potency and duration) and 
bupivacaine (high potency and duration). Increasing the drug concentration (e.g., 1% 
lidocaine vs 2% lidocaine), can increase the duration but can also increase the medication’s 
potency this in turn can increase the risk of toxicity and motor nerve involvement (loss of 
muscle power) [22]. Transdermal lidocaine, via either ointment or patch, has a long duration 
of action but also has some negative factors. The disadvantages are the low depth of skin 
penetration limits medication usage to topical surface structures such as the knee joint, and 
the gel or patch occasionally does not fit the treated location nor stay in place.
Systemic anesthetic usage has very few indications in the treatment of chronic pain. One 
such group of pain diagnoses is chronic neuropathic pain. Broader indications for their use 
are with cardiac arrhythmic care. However, the window between toxicity and clinically 
useful dosing for systemic anesthetics is very narrow. Local anesthetics are safer than 
general or systemic anesthetics; therefore, they are used whenever possible. In addition, 
local anesthetics are relatively easy to administer and readily available. However, high doses 
of local anesthetics also have significant side effects as discussed before. One such 
anesthetic with some limitations due to toxicity is bupivacaine and its application in joint 
injections [23]. This has not been determined for muscle or nerve tissues and as such 
bupivacaine is used for diagnosis and treatment for some painful conditions associated with 
these tissues. Bupivacaine is long acting so it does have value, but a long acting 1 or 2% 
lidocaine could be used in its place when toxicities or allergies are a concern.
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In summary, the use of long-acting local anesthetics that elicit complete neural blockage for 
several hours to days is highly desirable in the management of acute and chronic pain [24]. 
Current research is focused on developing controlled release strategies to prolong the action 
of the existing anesthetic molecules over a period of days rather than hours, with reduced 
side effects, to significantly enhance their utility in pain management.
Responsive hydrogels
It has been widely acknowledged that responsive hydrogels may have potential in the 
biomedical and pharmaceutical fields as a minimally invasive delivery system with 
controlled release properties [25–27]. Hydrogels are cross-linked networks of hydrophilic 
polymers with very high water content [28]. The tissue-mimic properties of hydrogel 
matrices have been shown to be effective in the controlled release of drugs as well as 
scaffolds for tissue engineering.
Recently, research has focused on developing ‘smart’ or ‘intelligent’ hydrogels that have the 
ability to respond to subtle changes in the surrounding environment [29–32]. The potential 
of ‘smart’ hydrogels stems from their ability to make rapid structural changes, volume-phase 
transitions or sol-gel transitions in response to certain stimuli [29,30,33]. Reactions may be 
triggered by a number of environmental changes, with the most extensively studied being 
thermo-responsive and pH-sensitive hydrogels [34]. Hydrogels have also been developed to 
respond to other external triggers such as light, ions, protein, DNA and electromagnetic 
radiation [28–34]. Recently, hydrogels have been developed that can respond 
simultaneously to multiple triggers, such as pH and temperature [35].
Thermo-sensitive hydrogels
Thermo-sensitive hydrogels are among the most heavily investigated type of stimuli-
responsive hydrogels due to their practical applications in vitro and in vivo [36–38]. 
Polymers with critical solution temperatures are of interest in drug delivery, particularly 
those with a lower critical solution temperature (LCST) at or near physiological temperature. 
These polymers near LCST exhibit a decrease in solubility resulting in sol-gel transition, 
and an LCST near 37°C allowing them to be injected and undergo gelation within the body.
One of the most widely studied LCST polymers is poly(N-isopropylacrylamide), 
(PNIPAAM) [39,40]. PNIPAAM is a synthetic water soluble polymer with an LCST of 
around 32°C in distilled water [41–43]. Studies have demonstrated the feasibility to 
modulate the chemistry of the polymer to adjust the LCST closer to the body temperature of 
37°C. The addition of hydrophilic co-monomers has been shown to increase the LCST of 
PNIPAAM whereas the addition of hydrophobic comonomers has been shown to decrease 
the LCST [44,45]. In spite of its unique properties, PNIPAAM has a number of limitations 
such as nondegradability and potential toxicity to serve as a suitable candidate for drug 
delivery [46].
Poly(ethylene glycol) (PEG) is another synthetic polymer extensively investigated to 
develop thermoresponsive hydrogels [47–51]. PEG is an ideal candidate to serve as the 
hydrophilic block in these hydrogel systems due to its biocompatibility, FDA approval status 
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and its availability in a variety of telechelic end groups. One of the most commonly 
investigated thermoresponsive PEG-based injectable hydrogel is poly(ethylene oxide)-
poly(propylene oxide)-poly(ethylene oxide) copolymers (Pluronic) [52]. However, the 
nondegradability and poor in vivo stability of the Pluronics are considered limitations for 
clinical applications [53]. Recent effort has therefore, been focused on developing 
biodegradable PEG-based injectable hydrogels with degradable hydrophobic blocks such as 
poly(ε-caprolactone), polyesters and polyurethanes [54–56].
Intra-molecular hydrogen bonding and hydrophobic interactions in natural biodegradable 
and biocompatible polymers, such as chitosan, have also been extensively investigated to 
develop thermo-sensitive polymers. For instance, acidic chitosan solutions, when neutralized 
at low temperature using β-glycerophosphate or ammonium hydrogen phosphate, remain in 
solution at room temperature and can undergo gelation at or near 37°C [57,58].
Photo responsive hydrogels
In photo responsive hydrogels, light serves as the stimuli to induce a sol-gel phase transition. 
Both ultraviolet (UV) and visible light have been extensively investigated. Photo responsive 
hydrogels that are stimulated by visible light provide advantages over UV induced hydrogels 
since they are readily available, safe and cost effective [29,46].
Visible light responsive hydrogels have been developed as a potential biomaterial with 
stimuli sensitive properties [59]. PNIPAAM hydrogels modified with chromophore, such as 
trisodium salt of copper chlorophyllin, have been shown to undergo differential swelling 
when irradiated with visible light. In the presence of visible light, the chromophore releases 
heat, thereby increasing the temperature of the polymer network. Since PNIPAAM hydrogel 
is thermo sensitive as discussed earlier, the increase in temperature impacts the swelling of 
the hydrogel and thereby affecting drug diffusion.
In addition to photo-responsive hydrogels, photo-cross-linked hydrogels are raising 
significant attention as drug delivery vehicles. Biodegradable, photo-curable polymers form 
a versatile class of injectable biomaterials as the aqueous polymer solution can be injected 
followed by photo-curing in situ using fiber optic cables. Several photo-curable 
biodegradable gel systems have been developed [60]. One of the limitations of photo-cross-
linkable systems is the light attenuation by the initiators, restricting the maximum attainable 
cure depth to only a few millimeters [61]. To circumvent the limitations of photo 
polymerized systems, several chemically cross-linked polymeric systems have been 
developed using functionalized polymers with reactive groups such as thiols, phenols and 
aldehydes [62–66].
pH-sensitive hydrogels
Changes in pH occur at a number of sites within the body including the stomach, intestine, 
lysosome, endosome and extracellular tumor sites [67–69]. These pH variations could 
therefore be used to trigger a site specific drug release from a pH responsive hydrogel. All 
pH-responsive hydrogels contain an ionizable acidic or alkaline group, which is able to 
respond to variations in pH or target specific tissue based on physiological pH [69]. When 
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ionized, these functional groups create a repulsion that results in the swelling of the 
hydrogel. The extent of the swelling of the hydrogel is determined by the degree to which 
the functional group in the polymer can be ionized [67]. Swelling will occur at the pKa of 
the functional group and has been found effective with groups with pKa’s ranging from 3 to 
10 [69]. Functional groups often found in pH sensitive hydrogels are weak acids or bases 
such as carboxylic acid, phosphoric acid, sulfonic acid and amines [30]. The most frequently 
studied pH responsive hydrogels are poly(acrylic acid) [70], poly(methacrylic acid) [71], 
poly(ethylene imine) [72], chitosan [73], poly(L–lysine) [74] and poly(L–histidine) due to 
the presence of carboxylic or amino groups in these polymers [75]. One of the limitations 
inherent in synthetic pH-sensitive hydrogels is that they are not biodegradable and therefore 
must be removed, thereby limiting their in vivo applications [46].
Hydrogels as localized anesthetic delivery systems
As discussed before, prolonged duration of local anesthetics is a significant current clinical 
need. Hydrogel systems have been extensively investigated for the sustained localized 
delivery of small molecules and macromolecules for various indications. These include 
growth factor delivery for tissue engineering, anti-cancer agents for localized chemotherapy 
and insulin delivery for diabetes [76]. Recently, significant interest has gone toward 
developing hydrogels as local anesthetic delivery vehicles due to the minimally invasive 
application possible with many injectable hydrogel systems, and the ability to localize the 
drug at the intended site [11] (Table 3).
Seol et al. developed a Pluronic F127/hyaluronic acid (HA) based gel with thermosensitive 
properties, which gels quickly upon exposure to body temperature, as a sustained delivery 
vehicle for a nonopioid local anesthetic, bupivacaine hydrochloride (BH) [77]. The authors 
demonstrated the feasibility of injecting and localizing the gel in situ, as well as the 
sustained release of the drug from the gel over a period of several days in vitro. The BH 
released from the gel was found to be less cytotoxic to L929 fibroblastic cells compared 
with adding BH directly to the culture media, presumably due to the slow release of BH 
from the gel. Similarly, Bernardo et al., developed a dual pH- and thermo-sensitive hydrogel 
system for the sustained delivery of bupivacaine [78]. The polymeric system used included 
copolymers of poly(acrylamide-co-monomethyl itaconate; A/MMI) cross-linked with N,N′-
methylene bisacrylamide (NBA). The swelling behavior of the hydrogel depended on the pH 
of the medium. Also during the initial stages both swelling and drug release kinetics were in 
accordance with the second Fick’s law. The system showed the feasibility to modulate the 
release profile of bupivacaine by changing the pH; a 60% release was observed at pH 7.5, 
whereas approximately 80% release was observed at pH 1.5. These pH sensitive hydrogels 
have the potential to serve as efficient delivery system to deliver analgesics to organs such 
as stomach that involves significant changes in pH.
As indicated before, long-lasting anesthetic is helpful during the post-operative period. Yin 
et al., investigated a composite hydrogel-nanoparticle system for the extended release of 
hydrophobic drugs, such as lidocaine [79]. Lidocaine was loaded into biodegradable PCL-
PEG-PCL (PCEC) nanoparticles, and the nanoparticles were then suspended in a 
thermogelling Pluronic solution. The thermogelling solution can be injected into the body, 
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where it gels upon exposure to the physiological temperature thereby localizing the 
nanoparticles to the point of application. A sustained drug release profile was observed due 
to the diffusion of the drug from the nanoparticles. The in vivo efficacy of the system was 
evaluated in subcutaneous rat model and measured by tail flick latency tests. The Lidocane-
nanogel produced effective anesthesia for 360 ± 13 min compared with lidocaine delivered 
directly from the gel (150 ± 33 min) and lidocaine solution (110 ± 45 min). Nano and 
microparticles have been previously explored as drug delivery vehicles for local anesthetics. 
The study demonstrated the potential of further improving the efficacy and localization of 
these carriers by combining them with hydrogel systems.
Similarly, Chen et al., developed an injectable microparticle-gel system for prolonged and 
localized release of lidocaine [80]. In this study, lidocaine-loaded degradable poly(lactic-co-
glycolic acid) microparticles were suspended in thermosensitive poloxamer 407 solution. 
The in vivo efficacy of the system was evaluated using a rat sciatic nerve blockade model by 
monitoring the sensory and motor functions. The study demonstrated that microsphere-
poloxamer formulation yielded the longest duration of sensory and motor block for a period 
of approximately 8.5 h compared with 5 h in the case of microspheres in saline, 5 h in the 
case of lidocaine in gel and 2 h by lidocaine in saline. The study corroborated the potential 
of multifaceted hydrogel system in developing long-lasting local analgesic formulations.
In another study, Jimenez-Kairuz et al., developed a sustained delivery lidoaine system 
using a carbomer (polyacrylic acid) based hydrogel [81]. The carbomerlidocaine system 
served as a reservoir of lidocaine wherein a high proportion of the drug existed in the form 
of R-COO-LH+. An in vitro release study demonstrated that the dissociation of ion pairs 
controlled the release rate of lidocaine. Moreover, the release rate can be increased by the 
addition of a second counter-ion or through the diffusion of neutral salts such as sodium 
chloride into the gel matrix. The study demonstrated that better understanding of the ion 
paring affinity between charged drug molecules and polyelectrolyte carriers would help to 
predict the release kinetics under different conditions. Loughlin et al., studied the role of 
polyol sugars in modulating the properties of tetra-hydroxyborate cross-linked poly(vinyl 
alcohol) gels as lidocaine delivery system [82]. Addition of the hydrochloride salt of 
lidocaine can lead to network constriction of poly(vinyl alcohol) induced by ionic and pH 
effects making it unsuitable for topical applications. The study demonstrated that the 
addition of D-mannitol can circumvent the problem. A formulation with 2% mannitol 
showed an initial burst release of lidocaine and a drug release mechanism dependent on 
temperature with a diffusion controlled release profile.
In addition to nanospheres, thermo-responsive nanogel systems have also been developed to 
achieve prolonged duration of local anesthesia [83]. The thermo-responsive nanogels were 
developed from PNIPAAM and their tunable size, number of functional groups, thermo-
responsiveness and anionic charge make them attractive candidates for prolonged drug 
release. In vivo studies using a rat sciatic nerve blockade model demonstrated nerve block 
durations of up to 9 h using acrylic acid conjugated nanogels loaded with bupivacaine. The 
study also demonstrated the feasibility to modulate the release by changing the composition 
and size of the nanogels. Increasing the anionic charge density of the nanogels and 
decreasing the nanogel size facilitated longer duration of anesthetic release.
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Apart from these nondegradable polymer systems, several injectable and degradable 
hydrogel systems have been developed for local anesthetic delivery. Jia et al., investigated 
the feasibility of using hydrazide and aldehyde modified HA as an injectable delivery 
vehicle for bupivacaine [84]. The efficacy of the system was evaluated in a rat sciatic nerve 
blockade model. It was reported that a 2% cross-linked HA doubled the duration of block of 
0.1–0.5% bupivacaine, without a statistically significant increase in myotoxicity. The 1% 
cross-linked HA also prolonged the nerve block compared with uncross-linked HA 
demonstrating the role of polymer cross-linking in prolonging the effect of local anesthetics.
Hoare et al., recently developed rheological polymer blends of HA and 
hydroxypropylmethyl cellulose (HPMC) as another approach to achieve sustained delivery 
of local anesthetics [85]. In a rat sciatic nerve blockade model, HA-HPMC loaded with 
bupivacaine prolonged the sensory block approximately threefold compared with 
bupivacaine solution. Incorporation of HPMC modulated the rheological property of the 
formulation, thereby allowing better polymer injection and reduced polymer hydration, 
leading to sustained drug release. Moreover, the blends exhibited no cytotoxicity in vivo 
with a mild short-term inflammatory reaction at the site of injection and were largely 
resorbed by four days post injection.
Pignatello et al., investigated the potential of chitosan glutamate hydrogels as localized 
anesthetic delivery vehicles for buccal application [86]. Chitosan hydrogels are known to 
prolong both the retention times on the oral mucosa as well as drug release. The anesthetic 
activity of mucoadhesive lidocaine-loaded chitosan gels was accessed in healthy volunteers 
and demonstrated its potential to reduce pain symptoms that characterize aphthosis and other 
mouth diseases.
We have investigated the feasibility of using thermogelling chitosan formulation as an 
injectable localized and sustained delivery vehicle for ropivacaine [11]. Ropivacaine (N-n-
propyl 2′,6′-pipecoloxylidide) is an amino-amide local anesthetic and is the propyl analogue 
of bupivacaine [87]. Numerous preclinical and clinical studies have demonstrated lower 
cardio- and neurotoxicity associated with ropivacaine compared with bupivacaine [88]. 
Ropivacaine is a pure S(-) enantiomer, while bupivacaine is a racemic mixture. Studies have 
shown that enantiomerically pure drugs are less toxic when compared with racemates [89]. 
The lipid solubility of ropivacaine is lower than bupivacaine, which should increase tissue 
retention. Ropivacaine also shows less vasodilation compared with bupivacaine and is 
capable of producing mild vasoconstriction, thus further reducing the extent of systemic 
plasma absorption. Another significant advantage of ropivacaine is its greater degree of 
separation between sensory and motor blockade resulting in less motor block compared with 
bupivacaine [90]. These attributes make ropivacaine an ideal molecule for localized 
anesthesia. The chitosan thermogels were prepared by neutralizing acidic chitosan solution 
with ammonium hydrogen phosphate at low temperature. At higher temperatures 
(approximately 37°C), the thermogelation of the neutral solution is promoted by the 
combined effect of electrostatic attraction and increased hydrophobic interactions between 
polymer chains. We have demonstrated that the use of ropivacaine nanoparticles with lower 
solubility, a drug action enhancer (dexamethasone) and a thermogel matrix together could 
lead to a multifaceted delivery system capable of providing moderate term pain management 
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[11]. Ropivacaine-based nanoparticles were prepared as described [91]. The controlled in 
vitro release of ropivacaine from the chitosan thermogel resulted in less than 50% of the 
drug being released after 7 days (Figure 1). Sensory blockade for animals given two doses of 
ropivacaine (75 and 150 mg/kg) along with dexamethasone in thermogel was found to be 
similar to animals given ropivacaine alone (5 and 150 mg/kg doses) in thermogel at 6 h; 
however, the blockade persisted much longer with slow return of sensory function over 24–
48 h in the case of (ropivacaine + dexamethasone) in the thermogel group (Figure 2). Thus, 
the delivery system demonstrated efficacy for more than 30 h in vivo, providing significant 
potential for clinical applications. Future studies will be focused on modulating the 
degradation kinetics of the injectable formulation to further control the drug release as well 
as the complete removal of the biomaterial after the intended application.
In spite of the unique properties of photoresponsive/cross-linked hydrogel delivery systems, 
they have not been extensively investigated for prolonged local anesthetic delivery. 
Literature search showed only one study evaluating the potential of a photocross-linked 
semi-interpenetrating network composed of poly(ethylene glycol) and gelatin to deliver 
bupivacaine and silver sulfadiazine for treating wound in a swine model [92]. The study 
demonstrated the feasibility to deliver these drugs from the hydrogel wound dressing and 
concluded that further optimization is required to determine the drug and carrier 
effectiveness.
Future perspective
Extended duration local anesthetic formulations are highly desirable for clinical use. The 
development of effective delivery systems capable of modulating the release rate of local 
anesthetic molecules and which enhances their localization could significantly increase the 
prolonged duration of activity and reduce systemic toxicity. Recent studies demonstrated the 
significant advantages in using injectable hydrogel systems for the localized prolonged 
delivery of local anesthetics. In spite of its unique properties, the current hydrogel systems 
can prolong the effectiveness of the drug only for few hours. The ultimate goal will be to 
achieve prolonged anesthesia for 7–30 days without cytotoxicity. Combination therapy 
involving local anesthetics/vasoconstrictors/NSAIDs along with injectable multifaceted 
delivery systems may in the near future provide the clinicians with a broader spectrum of 
formulations with varying degree of prolongation of anesthesia.
Key terms
Local anesthetics Anesthetics which cause loss of sensation only to the area to which 
it is applied
Controlled delivery Method to release drug over a period of time in a controlled 
manner
Bupivacaine An aminoamide local anesthetic drug
Hydrogels Cross-linked polymer network containing aqueous solution
Lidocaine A common local anesthetic drug
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Ropivacaine A long-acting local anesthetic structurally related to Bupivacaine
Thermogels Temperature sensitive hydrogels
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Executive summary
Introduction
• Reducing the acute and chronic pain commonly associated with injuries and 
diseases using analgesics has been shown to improve healing and is, therefore, a 
topic of great interest.
• Local application of analgesics has potential advantages compared to systemic 
administration, including the use of smaller dosages to reduce side effects and 
potential toxicity.
• Biomaterial-based controlled delivery systems have the potential to extend the 
activity of fast-acting local analgesics, in order to develop a safe, localized, 
long-acting pain management system.
Long acting local anesthetics for orthopaedic applications
• A long-lasting local anesthetic (relief for 7–20 days) is desirable for the 
treatment of chronic local pain.
• Current research is focused on developing controlled local release strategies to 
maintain an optimal therapeutic level of anesthetic over a period of days, to 
produce effective analgesia localized to the site of interest, and to restrict 
negative side effects.
Responsive hydrogels
• Hydrogels (cross-linked networks of hydrophilic polymers with high water 
content) have potential as local, minimally invasive, controlled release delivery 
systems due to their structure.
• Responsive hydrogels are those able to change properties in response to 
environmental stimuli such as temperature or pH.
• Thermo-sensitive hydrogels transition from a liquid to gel state as the 
temperature increases over a critical solution temperature specific to the 
polymer.
• Hydrogels can be modified to be light-sensitive or photo-crosslinked to allow 
for stimulation of gelation via exposure to visible/UV light or photo-curing, 
respectively.
• pH-responsive hydrogels contain ionizable functional groups that can respond to 
physiological variations in pH, promoting swelling of the hydrogel correlating 
to the degree of ionization.
• Responsiveness can be altered by altering the chemical structure of the 
polymers, potentially allowing engineered polymers to achieve a specific 
response desired for a given application.
Hydrogels as localized anesthetic delivery systems
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• The ability to localize drug delivery through minimally invasive administrations 
of hydrogels makes injectable hydrogel systems promising candidates for 
sustained, localized anesthetic delivery.
• A variety of responsive hydrogel systems for administration of bupivacaine, 
ropivacaine, and lidocaine have been investigated through in vitro and in vivo 
models, and have shown indications of controlled release, prolonged analgesic 
effects, and low cytotoxicity.
Future perspective
• There exists the potential for acute and chronic pain control using injectable 
hydrogel systems with a localized prolonged delivery of anesthetics, without 
systemic toxicity.
• The goal of current research is to modify the hydrogel systems in order to 
achieve a longer duration of anesthesia (7–30 days) without cytotoxicity.
• Composite hydrogel-nano/microparticle systems may continue to be studied in 
order to enhance efficacy, drug release kinetics, and localization capabilities of 
hydrogel therapies during post-operative periods.
• Future research may also explore novel therapies that combine local anesthetics, 
vasoconstrictors, NSAIDs, and injectable multi-faceted delivery systems to 
provide clinicians with a variety of approaches to prolong anesthesia for the 
duration needed.
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Figure 1. Ropivacaine base released from chitosan thermogel as determined by high-
performance liquid chromatography
The thermogel mediated a gradual release of the drug nanoparticles over the course of 7 
days. Data are presented as mean ± standard deviation (N = 3).
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Figure 2. In vivo efficacy of the delivery system
(A) Thermal paw withdrawal latency difference and (B) composite motor function score for 
animals rats given different anesthetic regimens (N ≥ 3). Chitosan thermogel delivery of 
ropivacaine base nanoparticles (C + RB-75 and C + RB-150) enhanced both in vivo sensory 
and motor blockade over the clinically utilized treatment (RHCl). Sensory blockade was 
extended and motor blockade was enhanced by the addition of dexamethasone to the 
localized anesthetic delivery system (C + RB-75 + D and C + RB-150 + D). p < 0.05 over 
RHCl (#) and C + D (+). Data are presented as mean ± standard error (N ≥ 3).
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Table 1
Classification of nonopioid local anesthetics.
Amino amides Amino esters Naturally derived local anesthetics
Articaine Amethocaine Cabratoxin
Bupivacaine Benzocaine Tetrodotoxin
Dibucaine Chloroprocaine Menthol
Etidocaine Cocaine Neosaxitoxin
Levobupivacaine Cyclomethycaine Saxitoxin
Lignocaine Dimethocaine
Mepivacaine Lidocaine
Prilocaine Piperocaine
Ropivacaine Propoxycaine
Procaine
Proparacaine
Tetracaine
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Table 2
Local anesthetics in treatment and diagnoses.
Local anesthetics assist with the diagnosis (and treatment) of: Local anesthetics assist with the relief of nonsurgical chronic pain in:
Facet joint mediated pain (Medial Branch Blocks) Sympathetically-mediated pain syndrome such as Complex Regional Pain 
Syndromes (CRPS)
Sacroiliac (SI) joint mediated pain Meralgia paresthetica
Localized myofacial pain syndromes- myofacial trigger points, 
piriformis syndrome
Occipital neuralgia
Diffuse myofacial pain syndrome- fibromyalgia tender points Post-herpetic neuralgia
Scar pain - post-epesiotomy, post-hernia repair, post- surgery
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Table 3
Hydrogels for prolonged local anesthetic delivery.
Name Type Ref.
Pluronics F127/hyaluronic acid Thermogel [77]
Poly(acrylamide-co-monomethyl itaconate) pH and thermosensitive gel [78]
PCL-PEG-PCL nanoparticles in Pluronics Thermogel [79]
Poly(Lactic-co-glycolic acid) microparticles in Poloxamer 407 Thermogel [80]
Poly(acrylic acid) Polyelectrolyte complex [81]
Poly(N-isopropyl acrylamide) Thermoresponsive nanogels [83]
Hyaluronic acid Chemical crosslinking [84]
Hyaluronic acid and hydroxypropylmethyl cellulose Rheological blend [85]
Chitosan-ammonium hydrogen phosphate Thermogel [11]
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